Adaptimmune Therapeutics Plc Net debt/EBITDA
What is the Net debt/EBITDA of Adaptimmune Therapeutics Plc?
The Net debt/EBITDA of Adaptimmune Therapeutics Plc is 7.00
What is the definition of Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA of companies in the Health Care sector on NASDAQ compared to Adaptimmune Therapeutics Plc
What does Adaptimmune Therapeutics Plc do?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Companies with net debt/ebitda similar to Adaptimmune Therapeutics Plc
- Jollibee Foods has Net debt/EBITDA of 6.98
- Adient plc has Net debt/EBITDA of 6.99
- CleanSpace has Net debt/EBITDA of 6.99
- Synthomer Plc has Net debt/EBITDA of 7.00
- Quectel Wireless Solutions Co., Ltd has Net debt/EBITDA of 7.00
- Spartan Delta has Net debt/EBITDA of 7.00
- Adaptimmune Therapeutics Plc has Net debt/EBITDA of 7.00
- Western Digital has Net debt/EBITDA of 7.00
- The Progressive has Net debt/EBITDA of 7.01
- Lear has Net debt/EBITDA of 7.01
- Valmont Industries has Net debt/EBITDA of 7.02
- theScore has Net debt/EBITDA of 7.02
- Intrasense SA has Net debt/EBITDA of 7.03